Abstract:Glioma is the most common malignant tumor in the central nervous system. The impact of metabolism on cancer development and the immune microenvironment landscape has recently gained broad attention. Purines are involved in multiple metabolic pathways. It has been proved that purine metabolism could regulate malignant biological behaviors and response to immune checkpoint inhibitors in multiple cancers. However, the relationship of purine metabolism with clinicopathological features and the immune landscape of glioma remains unclear. In this study, we explored the relationships between the expression of purine metabolism-related genes (PuMGs) and tumor features, including prognosis and microenvironment of glioma, based on analyses of 1,523 tumors from 4 public databases and our cohort. Consensus clustering based on 136 PuMGs classified the glioma patients into two clusters with significantly distinguished prognosis and immune microenvironment landscapes. Increased immune infiltration was associated with more aggressive gliomas. The prognostic Purine Metabolism-Related Genes Risk Signature (PuMRS), based on 11 critical PuMGs, stratified the patients into PuMRS low- and high-risk groups in the training set and was validated by validation sets from multiple cohorts. The high-risk group presented with significantly shorter overall survival, and further survival analysis demonstrated that the PuMRS was an independent prognostic factor in glioma. The nomogram combining PuMRS and other clinicopathological factors showed satisfactory accuracy in predicting glioma patients’ prognosis. Furthermore, analyses of the tumor immune microenvironment suggested that higher PuMRS was correlated with increased immune cell infiltration and gene expression signatures of “hotˮ tumors. Gliomas in the PuMRS high-risk group presented a higher expression level of multiple immune checkpoints, including PD-1 and PD-L1, and a better-predicted therapy response to immune checkpoint inhibitors. In conclusion, our study elucidated the relationship between the expression level of PuMGs and the aggressiveness of gliomas. Our study also endorsed the application of PuMRS to construct a new robust model for the prognosis evaluation of glioma patients. The correlations between the profiles of PuMGs expression and tumor immune microenvironment potentially provided guidance for immunotherapy in glioma.

Energy metabolism-related GLUD1 contributes to favorable clinical outcomes of IDH-mutant glioma

Increased RLIP76 Expression in IDH1 Wild‑type Glioblastoma Multiforme is Associated with Worse Prognosis

Identification of an energy metabolism-related signature associated with clinical prognosis in diffuse glioma

Abstract. Mutation of the isocitrate dehydrogenase (IDH) gene is regarded a novel indicator for the prognosis of patients with glioma. However, the role of the IDH1 gene mutations in carcinogenesis and the mechanisms underlying their function in glioblastoma multiforme

Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses

Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas

Development of a Novel Glycolysis-Related Genes Signature for Isocitrate Dehydrogenase 1-Associated Glioblastoma Multiforme.

Metabolic-related gene pairs signature analysis identifies ABCA1 expression levels on tumor-associated macrophages as a prognostic biomarker in primary IDHWT glioblastoma

Glutamine metabolism-related genes predict prognosis and reshape tumor microenvironment immune characteristics in diffuse gliomas

Identification of an Energy Metabolism-Related Six-Gene Signature for Distinguishing and Forecasting the Prognosis of Low-Grade Gliomas

Identification of a Glycolysis-Related LncRNA Signature to Predict Survival in Diffuse Glioma Patients

Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations

Comprehensive Analyses of Glucose Metabolism in Glioma Reveal the Glioma-Promoting Effect of GALM

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

IDH1 Mutation is Associated with Improved Overall Survival in Patients with Glioblastoma: a Meta-Analysis

1242 Metabologenomic Characterization Uncovers Heterogeneity Amongst IDH Mutant Gliomas

Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas

Uridine phosphorylase 1 is a novel immune-related target and predicts worse survival in brain glioma

Identification of tumor microenvironment-related genes in lower-grade gliomas by mining TCGA database

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma